Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Nab-paclitaxel, and Levocetirizine in Advanced TNBC
NCT06632405Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of levocetirizine in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
levocetirizine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06632405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632405.